SAT493 Laser Ablation For Benign Thyroid Nodules: A Way To Treat And Still Preserve The Thyroid

Abstract Disclosure: N. Kalara: None. D.L. Bignoli: None. C.M. Acosta: None. A. Manzano: None. Introduction: Thyroid nodules in adults have a prevalence of 3-7% based on palpation and 20-76% based on ultrasound examination. The majority of which are benign but some increase in size causing compressi...

Full description

Saved in:
Bibliographic Details
Published inJournal of the Endocrine Society Vol. 7; no. Supplement_1
Main Authors Kalara, Niketa, Maria Bignoli, Daniela Laura, Acosta, Crystal Maria, Manzano, Alex
Format Journal Article
LanguageEnglish
Published US Oxford University Press 05.10.2023
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Abstract Disclosure: N. Kalara: None. D.L. Bignoli: None. C.M. Acosta: None. A. Manzano: None. Introduction: Thyroid nodules in adults have a prevalence of 3-7% based on palpation and 20-76% based on ultrasound examination. The majority of which are benign but some increase in size causing compressive symptoms or cosmetic concerns, thus, needing treatment. Laser ablation (LA) is a safe, non-surgical approach for the management of benign thyroid nodules now approved in the US. Nodule reduction is achieved through laser induced cytoreduction and tissue coagulation. Two benign FNA biopsies 3-6 months apart and a nodule size of more than 2.5 cm are some of the inclusion criteria for LA. We present a case of a benign thyroid nodule causing compressive symptoms where LA was done since the patient declined surgery. Case description: 76-year-old female with a history of type 2 diabetes mellitus, hypertension, and multinodular goiter for many years presented with concerns of neck fullness and discomfort for the past 6 months. Thyroid ultrasound confirmed a large dominant right complex nodule of 2.8 x 1.13 x 3 cm with a volume of 5 ml. Thyroid function test showed Thyroid stimulating hormone (TSH) 1.2 mIU/mL (0.40-4.50) and free T4 1.24 ng/dl (0.9-1.7). Two FNA biopsies done 3 months apart in the past were Bethesda II. Given the compressive symptoms due to a multinodular gland thyroidectomy was discussed as a treatment option with the patient which she declined. Hence, LA was discussed as an option for the largest nodule. The procedure was performed without complications. The nodule received 1450 Joules at 6 watts using one Elesta laser fiber. At the end of 2 months post-LA, thyroid ultrasound showed a significant reduction of the nodule with a current size of 1.5 x 1 x 1.6 cm and 1.4ml volume. She continued to be clinically and biochemically euthyroid with a total volume reduction close to 70% and complete resolution in compressive symptoms. Conclusion: Percutaneous laser ablation is a non-surgical, minimally invasive procedure to treat benign thyroid nodules that is now accessible in the US with promising results and a good safety profile. It is covered by insurance in various states. In our case the patient refused surgical intervention, thus, laser ablation was done that resulted in the resolution of her compressive symptoms without any complications. More awareness regarding the laser ablation procedure and its availability for patients is needed, especially in cases where preservation of the thyroid gland is desired. Reference: 1. Gambelunghe G, Stefanetti E, Avenia N, De Feo P. Percutaneous Ultrasound-Guided Laser Ablation of Benign Thyroid Nodules: Results of 10-Year Follow-Up in 171 Patients. J Endocr Soc. 2021 May 5;5(7):bvab081. doi: 10.1210/jendso/bvab081. PMID: 34159286; PMCID: PMC8212682. Presentation Date: Saturday, June 17, 2023
AbstractList Abstract Disclosure: N. Kalara: None. D.L. Bignoli: None. C.M. Acosta: None. A. Manzano: None. Introduction: Thyroid nodules in adults have a prevalence of 3-7% based on palpation and 20-76% based on ultrasound examination. The majority of which are benign but some increase in size causing compressive symptoms or cosmetic concerns, thus, needing treatment. Laser ablation (LA) is a safe, non-surgical approach for the management of benign thyroid nodules now approved in the US. Nodule reduction is achieved through laser induced cytoreduction and tissue coagulation. Two benign FNA biopsies 3-6 months apart and a nodule size of more than 2.5 cm are some of the inclusion criteria for LA. We present a case of a benign thyroid nodule causing compressive symptoms where LA was done since the patient declined surgery. Case description: 76-year-old female with a history of type 2 diabetes mellitus, hypertension, and multinodular goiter for many years presented with concerns of neck fullness and discomfort for the past 6 months. Thyroid ultrasound confirmed a large dominant right complex nodule of 2.8 x 1.13 x 3 cm with a volume of 5 ml. Thyroid function test showed Thyroid stimulating hormone (TSH) 1.2 mIU/mL (0.40-4.50) and free T4 1.24 ng/dl (0.9-1.7). Two FNA biopsies done 3 months apart in the past were Bethesda II. Given the compressive symptoms due to a multinodular gland thyroidectomy was discussed as a treatment option with the patient which she declined. Hence, LA was discussed as an option for the largest nodule. The procedure was performed without complications. The nodule received 1450 Joules at 6 watts using one Elesta laser fiber. At the end of 2 months post-LA, thyroid ultrasound showed a significant reduction of the nodule with a current size of 1.5 x 1 x 1.6 cm and 1.4ml volume. She continued to be clinically and biochemically euthyroid with a total volume reduction close to 70% and complete resolution in compressive symptoms. Conclusion: Percutaneous laser ablation is a non-surgical, minimally invasive procedure to treat benign thyroid nodules that is now accessible in the US with promising results and a good safety profile. It is covered by insurance in various states. In our case the patient refused surgical intervention, thus, laser ablation was done that resulted in the resolution of her compressive symptoms without any complications. More awareness regarding the laser ablation procedure and its availability for patients is needed, especially in cases where preservation of the thyroid gland is desired. Reference: 1. Gambelunghe G, Stefanetti E, Avenia N, De Feo P. Percutaneous Ultrasound-Guided Laser Ablation of Benign Thyroid Nodules: Results of 10-Year Follow-Up in 171 Patients. J Endocr Soc. 2021 May 5;5(7):bvab081. doi: 10.1210/jendso/bvab081. PMID: 34159286; PMCID: PMC8212682. Presentation Date: Saturday, June 17, 2023
Disclosure: N. Kalara: None. D.L. Bignoli: None. C.M. Acosta: None. A. Manzano: None. Introduction : Thyroid nodules in adults have a prevalence of 3-7% based on palpation and 20-76% based on ultrasound examination. The majority of which are benign but some increase in size causing compressive symptoms or cosmetic concerns, thus, needing treatment. Laser ablation (LA) is a safe, non-surgical approach for the management of benign thyroid nodules now approved in the US. Nodule reduction is achieved through laser induced cytoreduction and tissue coagulation. Two benign FNA biopsies 3-6 months apart and a nodule size of more than 2.5 cm are some of the inclusion criteria for LA. We present a case of a benign thyroid nodule causing compressive symptoms where LA was done since the patient declined surgery. Case description : 76-year-old female with a history of type 2 diabetes mellitus, hypertension, and multinodular goiter for many years presented with concerns of neck fullness and discomfort for the past 6 months. Thyroid ultrasound confirmed a large dominant right complex nodule of 2.8 x 1.13 x 3 cm with a volume of 5 ml. Thyroid function test showed Thyroid stimulating hormone (TSH) 1.2 mIU/mL (0.40-4.50) and free T4 1.24 ng/dl (0.9-1.7). Two FNA biopsies done 3 months apart in the past were Bethesda II. Given the compressive symptoms due to a multinodular gland thyroidectomy was discussed as a treatment option with the patient which she declined. Hence, LA was discussed as an option for the largest nodule. The procedure was performed without complications. The nodule received 1450 Joules at 6 watts using one Elesta laser fiber. At the end of 2 months post-LA, thyroid ultrasound showed a significant reduction of the nodule with a current size of 1.5 x 1 x 1.6 cm and 1.4ml volume. She continued to be clinically and biochemically euthyroid with a total volume reduction close to 70% and complete resolution in compressive symptoms. Conclusion : Percutaneous laser ablation is a non-surgical, minimally invasive procedure to treat benign thyroid nodules that is now accessible in the US with promising results and a good safety profile. It is covered by insurance in various states. In our case the patient refused surgical intervention, thus, laser ablation was done that resulted in the resolution of her compressive symptoms without any complications. More awareness regarding the laser ablation procedure and its availability for patients is needed, especially in cases where preservation of the thyroid gland is desired. Reference: 1. Gambelunghe G, Stefanetti E, Avenia N, De Feo P. Percutaneous Ultrasound-Guided Laser Ablation of Benign Thyroid Nodules: Results of 10-Year Follow-Up in 171 Patients. J Endocr Soc. 2021 May 5;5(7):bvab081. doi: 10.1210/jendso/bvab081. PMID: 34159286; PMCID: PMC8212682. Presentation Date: Saturday, June 17, 2023
Author Kalara, Niketa
Manzano, Alex
Maria Bignoli, Daniela Laura
Acosta, Crystal Maria
Author_xml – sequence: 1
  givenname: Niketa
  surname: Kalara
  fullname: Kalara, Niketa
– sequence: 2
  givenname: Daniela Laura
  surname: Maria Bignoli
  fullname: Maria Bignoli, Daniela Laura
– sequence: 3
  givenname: Crystal Maria
  surname: Acosta
  fullname: Acosta, Crystal Maria
– sequence: 4
  givenname: Alex
  surname: Manzano
  fullname: Manzano, Alex
BookMark eNpVkF9LwzAUR4MoOOc-gS_5At3yr2vji9ThVBgqrOJjSJrbraNLRtIN9u3d2BR9uj-4nPNwbtCl8w4QuqNkSBkloxU4G_3I7LSlVAypHI8vUI-JjCVUZuzyz75GgxhXhBAquZBC9JCaF6WQHM90hIAL0-qu8Q5PfcCP4JqFw-VyH3xj8Zu32xbiPS7wl97j0uMygO5w4Syed03b4o8AB8kODgj8YLfoqtZthMH59tHn9KmcvCSz9-fXSTFLKirScVJXRnOTQ51RkuUpz3NSS2CpzgUwyytta17nMqNaCmaYTUlljTCESWIZyTTvo4eTd7M1a7AVuC7oVm1Cs9Zhr7xu1P-Pa5Zq4XeKkjQVOZcHAz8ZquBjDFD_wpSoY2h1Cq3OodUxNP8GvBB2EA
ContentType Journal Article
Copyright The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. 2023
Copyright_xml – notice: The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. 2023
DBID AAYXX
CITATION
5PM
DOI 10.1210/jendso/bvad114.1966
DatabaseName CrossRef
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
DatabaseTitleList CrossRef

DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2472-1972
ExternalDocumentID 10_1210_jendso_bvad114_1966
GroupedDBID 0R~
53G
AAFWJ
AAPPN
AAPXW
AAVAP
AAYXX
ABPTD
ABXVV
ACGFS
ADBBV
AENZO
AFPKN
AFULF
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAYMD
BCNDV
BTTYL
CITATION
EBS
EMOBN
GROUPED_DOAJ
HYE
IAO
ITC
KQ8
KSI
ML0
M~E
O9-
OK1
ROX
RPM
TJX
TOX
5PM
ID FETCH-LOGICAL-c1456-fcba3b8ef7107853880f9e25a84e2d3cadf3f8971a942b2d50cdb4b0290d207a3
IEDL.DBID RPM
ISSN 2472-1972
IngestDate Tue Sep 17 21:29:26 EDT 2024
Thu Sep 26 15:59:52 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue Supplement_1
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c1456-fcba3b8ef7107853880f9e25a84e2d3cadf3f8971a942b2d50cdb4b0290d207a3
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554839/
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_10554839
crossref_primary_10_1210_jendso_bvad114_1966
PublicationCentury 2000
PublicationDate 2023-10-05
20231005
PublicationDateYYYYMMDD 2023-10-05
PublicationDate_xml – month: 10
  year: 2023
  text: 2023-10-05
  day: 05
PublicationDecade 2020
PublicationPlace US
PublicationPlace_xml – name: US
PublicationTitle Journal of the Endocrine Society
PublicationYear 2023
Publisher Oxford University Press
Publisher_xml – name: Oxford University Press
SSID ssj0001934944
Score 2.2766948
Snippet Abstract Disclosure: N. Kalara: None. D.L. Bignoli: None. C.M. Acosta: None. A. Manzano: None. Introduction: Thyroid nodules in adults have a prevalence of...
Disclosure: N. Kalara: None. D.L. Bignoli: None. C.M. Acosta: None. A. Manzano: None. Introduction : Thyroid nodules in adults have a prevalence of 3-7% based...
SourceID pubmedcentral
crossref
SourceType Open Access Repository
Aggregation Database
SubjectTerms Thyroid
Title SAT493 Laser Ablation For Benign Thyroid Nodules: A Way To Treat And Still Preserve The Thyroid
URI https://pubmed.ncbi.nlm.nih.gov/PMC10554839
Volume 7
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bS8MwGA3bHsQX8YrzMvLgo916SZvGtzocIm4K63BvJWkSV5mtjCn47_3Si9hXX0qhfNCepJzztScnCF0R6YQqVI6llQosYDzfErbSFteUMy5MYLhpFKez4H5BHpb-soOCZi1MadpPRTbM1-_DPFuV3sqP93TU-MRGz9Ox2dSRALOPuqhLPe9Pj15-WWEmcoXUEUNmicqbcZcWI_HFJcj_IUy6oEVDbTvkH36Z7KO9WhjiqLqBA9RR-SHamda_vo9QMo9iwjz8CLSzwZGoPGx4Umzwrcqz1xzHq-9NkUk8K-QnPMINjvAL_8ZxgWOjDHGUSzzfZus1Nr4L43SEEtWUHaPF5C4e31v17ghW6oDqsXQquCdCpUEjUCBdeBE1U67PQ6Jc6aVcak-HjDqcEVe40rdTKYiwXWZL16bcO0G9vMjVKcJUOgET2ucgV4hHbUbhjBAZgHwkKad9dN2AlXxUIRiJaR4A26TCNqmxTQy2fRS2AP2tMVHW7SswwmWkdTOiZ_8vPUe7Ziv40mjnX6DedvOpLkEwbMWgbLQH5SyBY_y0_AF_TMXs
link.rule.ids 230,315,733,786,790,870,891,27957,27958,53827,53829
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NT9wwEB0BlYBLaYGqfLT40GOTzYcTx9wCYrWlu6tKBMEtsmMb0i4JWu1Wgl_POB8V21t7i2SNbOXZmjfJ8xuAL1T5iU607xitYwczXuRITxtHGCa4kNYw3BaKk2k8uqaXt9HtGsT9XZhGtF_I0q1mD25V3jfayseHYtDrxAY_Jue2qSPFzD5Yhzd4YAP2qkpvvq1wa7pCO5Mhe0nlp9WX1gP5WygsAFzcdvFKIloVRL7KMMMduOnX1gpLfrnLhXSL579sG_998e_gbUc6SdqOv4c1Xe3C5qT7rb4H-VWaUR6SMaa0OUllq48jw3pOznRV3lUku3-a16Ui01otcYZTkpIb8USymmSWdZK0UuRqUc5mxGo6rIoSQ3Qftg_Xw4vsfOR0nRecwkdG5ZhCilAm2iD_YJjQ8ZAbroNIJFQHKiyEMqFJOPMFp4EMVOQVSlLpBdxTgcdE-AE2qrrSH4Ew5cdcmkggFaIh8zjDJ0pVjNSUFoIdwNcehvyxNdjIbWGCqOUtanmHWm5RO4BkBao_MdYme3UEAWjssvsXfvj_oSewNcom43z8bfr9CLZty_lG0Bcdw8ZivtSfkJgs5OdmF74AJRDmBw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1JT9wwGLUoSKgXli6CsvnQY7M7i3sLywjamRHSZFSkHiI7tiEwOKPpTCX49XzOgmY4couUfMrybL33JS_PCH0nwktkIj1LSRlZwHihxV2pLKZiRhk3geGmURwMo8sx-XUT3rSuyn-trVIXvLT15NHW5V3trZw-Fk7nE3OuB2dmUUcCzO5MhXI-oA2YtD5d6tTr9yvUBK-QNmjI_KhybzymlcP_MwFNgA1DL1oho1VT5BLL9LbR3-76GnPJg72Yc7t4fhPd-L4b2EFbrfjEaXPMLlqT-hPaHLSf1z-jfJRmhAa4D9Q2wylvfHK4V83wqdTlrcbZ3dOsKgUeVmIBZ_mJU_yHPeGswplRnzjVAo_m5WSCjbfDuCmhRHZlX9C4d5GdXVrtCgxW4YGyslTBWcATqUCHxEDsMNkVlX7IEiJ9ERRMqEAlNPYYJT73RegWghPu-tQVvhuz4Cta15WWewjHwosoVyEDSUSC2KUxbBEiIpCopGDxPvrRQZFPm6CN3DQogFzeIJe3yOUGuX2UrMD1WmPislf3AAh1bHb30L-9v_QEbV6f9_L-1fD3AfpoVp6vfX3hIVqfzxbyCPTJnB_XA_EFaRrohw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=SAT493+Laser+Ablation+For+Benign+Thyroid+Nodules%3A+A+Way+To+Treat+And+Still+Preserve+The+Thyroid&rft.jtitle=Journal+of+the+Endocrine+Society&rft.au=Kalara%2C+Niketa&rft.au=Maria+Bignoli%2C+Daniela+Laura&rft.au=Acosta%2C+Crystal+Maria&rft.au=Manzano%2C+Alex&rft.date=2023-10-05&rft.issn=2472-1972&rft.eissn=2472-1972&rft.volume=7&rft.issue=Supplement_1&rft_id=info:doi/10.1210%2Fjendso%2Fbvad114.1966&rft.externalDBID=n%2Fa&rft.externalDocID=10_1210_jendso_bvad114_1966
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2472-1972&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2472-1972&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2472-1972&client=summon